058110.Kq
The company designs, develops, and sells advanced medical equipment and technology, primarily generating revenue through the sale of diagnostic imaging systems and related services.
Business. The company designs, develops, and sells advanced medical equipment and technology, primarily generating revenue through the sale of diagnostic imaging systems and related services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company designs, develops, and sells advanced medical equipment and technology, primarily generating revenue through the sale of diagnostic imaging systems and related services.
The company's capital structure is characterized by a debt-to-equity ratio of 0.44, indicating a relatively conservative leverage position compared to the industry median of 0.65. However, the company's liquidity is rated as medium, with negative net cash after subtracting total debt, and a current ratio of 1.23, which is below the industry median of 1.50. The company's market price of 2465.0 KRW results in a price-to-book ratio of 1.04, suggesting a valuation close to its book value.
Profitability metrics show a challenging performance, with a return on equity of -6.92% and a return on assets of -4.51%, both significantly below the industry median of 12.5% and 8.2%, respectively. The company reported a net loss of 2,534,479,210 KRW and an operating loss of 2,787,134,560 KRW, reflecting a deteriorating financial position. Gross profit of 6,155,138,470 KRW is also below the industry median of 7.8% of revenue.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's revenue concentration in a single segment is higher than the industry median of 60%, indicating a higher concentration risk.
The company's growth trajectory is negative, with a projected revenue decline in the current fiscal year. Historical revenue data shows a decline in the most recent period, and the outlook for the next fiscal year is also negative. The company's capital expenditure of -96,326,410 KRW indicates a reduction in investment, which may affect long-term growth potential.
Risk factors include a high liquidity risk due to negative net cash and a current ratio below the industry median. The company's dilution risk is rated as low, with no near-term pressure expected. However, the company's operating cash flow of -2,464,021,640 KRW and free cash flow of -1,535,438,490 KRW indicate a cash flow challenge that could necessitate future financing.
Recent events include a significant operating loss and a net loss, as disclosed in the latest financial filing. The company has not issued any recent transcripts or press releases indicating strategic changes or new product launches. The absence of recent positive developments suggests a period of financial stress and operational challenges.
- The company is operating at a loss, with a return on equity of -6.92% and a return on assets of -4.51%.
- The company's liquidity is rated as medium, with a current ratio of 1.23 and negative net cash after subtracting total debt.
- Revenue is concentrated in a single business segment, increasing exposure to regional and sector-specific risks.
- The company's growth trajectory is negative, with a projected revenue decline in the current fiscal year.
- The company's capital expenditure is negative, indicating a reduction in investment and potential long-term growth challenges.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 058110.KQ Market data — financials · 2026-05-26